Commodity Channel Index
|Bid||0.0000 x 3100|
|Ask||0.0000 x 3100|
|Day's Range||2.4400 - 2.6300|
|52 Week Range||1.0000 - 8.7700|
|Beta (5Y Monthly)||3.42|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 04, 2020 - Aug 10, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||2.78|
Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that the Cardiovascular and Renal Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will, as expected, hold a virtual meeting to review data on terlipressin, an investigational agent being evaluated for the treatment of hepatorenal syndrome type 1 (HRS-1). The company announced the FDA accepted for review its New Drug Application (NDA) for terlipressin in April.
In this article you are going to find out whether hedge funds think Mallinckrodt Public Limited Company (NYSE:MNK) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus […]
“Opioid risk is coming back,” says analyst Navann Ty, who lowered her rating on the drugmaker to Sell in the face of a lawsuit and a separate investigation by the state.
Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, will present on Tuesday, June 23, 2020 at the BMO Prescriptions for Success Healthcare Conference. Mark Trudeau, President and Chief Executive Officer, and Bryan Reasons, Executive Vice President and Chief Financial Officer, will represent the company in a fireside chat at 8:00 a.m. Eastern Time. To access the webcast, please refer to the webcast link posted on our site at: http://www.mallinckrodt.com/investors. A replay of the fireside chat will also be available following the meeting.
Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, announced its disappointment with the U.S. Court of Appeals for the District of Columbia decision to deny its request for a temporary injunction preventing the U.S. Centers for Medicare and Medicaid Services (CMS) from enforcing a change in Medicaid drug rebate calculation for Acthar® Gel (repository corticotropin injection). Mallinckrodt had asked for the temporary injunction as it appeals a lower court ruling that allowed CMS to reset the base date average manufacturer price (AMP). The Appeals Court also ordered an expedited briefing and oral argument schedule that will likely lead to fall oral arguments, and potentially a ruling by end of year.
Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced it will present data from the pivotal Phase 3 clinical trial (STRATA2016) of its investigational product StrataGraft®, a regenerative skin tissue therapy in development for the treatment of deep partial-thickness thermal burns, as well as health economics and outcomes research (HEOR) and other data on the treatment of burns as part of the virtual American Burn Association (ABA) 52nd Annual Meeting. The virtual meeting begins today and is accessible online for attendees during the next 90 days. StrataGraft skin tissue is an investigational product, and its safety and effectiveness have not yet been established by the U.S. Food and Drug Administration (FDA).
Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced publication of findings from a medical chart study to assess the real-world use of terlipressin and other vasopressors in hospitalized patients with hepatorenal syndrome type 1 (HRS-1), an acute and life-threatening syndrome involving acute kidney failure in people with cirrhosis.1 The study, funded by Mallinckrodt, found that terlipressin was associated with an improvement in kidney function among HRS-1 patients as measured by a reduction in serum creatinine (SCr). The results of the study were published in the peer-reviewed journal Alimentary Pharmacology and Therapeutics.
Mallinckrodt (MNK) completes the rolling submission of a BLA for StrataGraft regenerative skin tissue to treat adults with deep partial-thickness thermal burns
Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that Stratatech, a Mallinckrodt company, has completed its rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for StrataGraft®, a regenerative skin tissue therapy in development for the treatment of adult patients with deep partial-thickness thermal burns. The company previously announced initiation of the rolling submission in April. StrataGraft skin tissue is an investigational product, and its safety and effectiveness have not yet been established by the FDA.
Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, announced today that it will appeal a ruling by the U.S. District Court for the District of Columbia in a lawsuit filed by its subsidiary, Mallinckrodt ARD LLC, against the U.S. Department of Health and Human Services (HHS) and the Centers for Medicare and Medicaid Services (CMS), regarding the Medicaid drug rebate calculation for Acthar® Gel (repository corticotropin injection).
Mallinckrodt (MNK) declines on sales miss in the first quarter and a challenging outlook for the remainder of the year despite reporting an earnings beat.
Ladies and gentlemen, thank you for standing by, and welcome to the Q1 2020 Mallinckrodt earnings conference call. Joining me this morning are Mark Trudeau, CEO; Steven Romano, our chief scientific officer; and Bryan Reasons, our CFO.
Mallinckrodt (MNK) delivered earnings and revenue surprises of 16.31% and -2.15%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Mallinckrodt (NYSE:MNK) were unchanged in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share decreased 15.46% over the past year to $1.64, which beat the estimate of $1.48.Revenue of $665,800,000 less by 15.79% year over year, which missed the estimate of $693,310,000.Looking Ahead Earnings guidance hasn't been issued by the company for now.Revenue guidance hasn't been issued by the company for now.Details Of The Call Date: May 05, 2020View more earnings on MNKWebcast URL: https://edge.media-server.com/mmc/p/u396hdtkPrice Action 52-week high: $17.4052-week low: $1.00Price action over last quarter: down 16.03%Company Description Mallinckrodt PLC develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Its areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. The company operates its business in two reportable segments namely Specialty Brands that includes innovative specialty pharmaceutical brands; and Specialty Generics that includes niche specialty generic drugs and active pharmaceutical ingredients.See more from Benzinga * 16 Healthcare Stocks Moving In Monday's Pre-Market Session * 20 Healthcare Stocks Moving In Wednesday's Pre-Market Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
First quarter net sales of $665.8 million, with diluted loss per share of $0.60, with results impacted in part by competitive and payer pressures in certain products and a decline in demand due to COVID-19
Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that its observational registry comparing the safety and effectiveness of INOmax® (nitric oxide) gas, for inhalation, in term and near-term neonates to that in preterm neonates with pulmonary hypertension (PH) was ended early due to achievement of the pre-specified primary outcome measure, non-inferiority (95 percent confidence interval: -0.0021, 0.1158, with a pre-defined margin of -0.1452). The decision was made following the second planned interim analysis at 75 percent enrollment. The company intends to share the results of this study in an appropriate scientific forum soon.
Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, announced today that it is supporting an investigator-initiated clinical study at Massachusetts General Hospital evaluating the potential benefits of inhaled nitric oxide as a treatment for pulmonary complications in patients infected with COVID-19. Mallinckrodt's support to Massachusetts General Hospital includes providing funding as well as INOmax® (nitric oxide) gas, for inhalation, to facilitate the study.
Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's New Drug Application (NDA) for terlipressin, an investigational agent being evaluated for the treatment of hepatorenal syndrome type 1 (HRS-1). On March 17, 2020 the company announced the completion of its rolling submission of the NDA for terlipressin. The FDA assigned a Prescription Drug User Fee Act (PDUFA) target date of September 12, 2020.
New York state brought civil charges on Tuesday accusing Mallinckrodt Plc of insurance fraud for misrepresenting the safety and efficacy of its opioid drugs, leading to medically unnecessary prescriptions. Governor Andrew Cuomo said the charges brought by New York's Department of Financial Services are the first against a major opioid manufacturer in the regulator's probe into entities that contributed to the nationwide opioid crisis. New York accused Mallinckrodt of overstating the benefits of long-term opioid treatment, downplaying the risks of addiction and abuse, and knowing its conduct would result in the payment of fraudulent insurance claims on unnecessary prescriptions.